326 related articles for article (PubMed ID: 37792452)
1. Risk Factors for Not Completing a 2-Dose Primary Series of Messenger RNA COVID-19 Vaccination in a Large Health Care System in Southern California: Retrospective Cohort Study.
Xu S; Hong V; Sy LS; Bruxvoort KJ; Lewin B; Han B; Holmquist KJ; Qian L
JMIR Public Health Surveill; 2023 Oct; 9():e46318. PubMed ID: 37792452
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system.
Bruxvoort KJ; Sy LS; Hong V; Lewin B; Qian L; Huang X; Holmquist KJ; Han B; Xu S
Vaccine; 2023 Nov; 41(49):7460-7468. PubMed ID: 37953096
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 Vaccination Coverage and Factors Associated With Vaccine Uptake Among People With HIV.
Hechter RC; Qian L; Liu IA; Sy LS; Ryan DS; Xu S; Williams JTB; Klein NP; Kaiser RM; Liles EG; Glanz JM; Jackson LA; Sundaram ME; Weintraub ES; Tseng HF
JAMA Netw Open; 2024 Jun; 7(6):e2415220. PubMed ID: 38842808
[TBL] [Abstract][Full Text] [Related]
4. Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Xie F; Ackerson BK; Takhar H; Ogun OA; Simmons S; Zamparo JM; Tseng HF; Jodar L; McLaughlin JM
JAMA Netw Open; 2023 Jan; 6(1):e2251833. PubMed ID: 36662525
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
[TBL] [Abstract][Full Text] [Related]
6. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans.
Young-Xu Y; Korves C; Roberts J; Powell EI; Zwain GM; Smith J; Izurieta HS
JAMA Netw Open; 2021 Oct; 4(10):e2128391. PubMed ID: 34613401
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R
JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390
[TBL] [Abstract][Full Text] [Related]
8. Analyses of reported severe adverse events after immunization with SARS-CoV-2 vaccines in the United States: One year on.
Mangat HS; Musah A; Luedtke S; Syed AA; Maramattom BV; Maruthanal J; Bosman A; Kostkova P
Front Public Health; 2022; 10():972464. PubMed ID: 36311588
[TBL] [Abstract][Full Text] [Related]
9. Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3-5 Years - Increasing Community Access to Testing Program, United States, July 2022-February 2023.
Fleming-Dutra KE; Ciesla AA; Roper LE; Smith ZR; Miller JD; Accorsi EK; Verani JR; Shang N; Derado G; Wiegand RE; Pilishvili T; Britton A; Link-Gelles R
MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(7):177-182. PubMed ID: 36795625
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccine coverage and factors associated with vaccine uptake among 23 247 adults with a recent history of homelessness in Ontario, Canada: a population-based cohort study.
Shariff SZ; Richard L; Hwang SW; Kwong JC; Forchuk C; Dosani N; Booth R
Lancet Public Health; 2022 Apr; 7(4):e366-e377. PubMed ID: 35278362
[TBL] [Abstract][Full Text] [Related]
11. Obstetric Complications and Birth Outcomes After Antenatal Coronavirus Disease 2019 (COVID-19) Vaccination.
Vesco KK; Denoble AE; Lipkind HS; Kharbanda EO; DeSilva MB; Daley MF; Getahun D; Zerbo O; Naleway AL; Jackson L; Williams JTB; Boyce TG; Fuller CC; Weintraub ES; Vazquez-Benitez G
Obstet Gynecol; 2024 Jun; 143(6):794-802. PubMed ID: 38626447
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
Thompson MG; Stenehjem E; Grannis S; Ball SW; Naleway AL; Ong TC; DeSilva MB; Natarajan K; Bozio CH; Lewis N; Dascomb K; Dixon BE; Birch RJ; Irving SA; Rao S; Kharbanda E; Han J; Reynolds S; Goddard K; Grisel N; Fadel WF; Levy ME; Ferdinands J; Fireman B; Arndorfer J; Valvi NR; Rowley EA; Patel P; Zerbo O; Griggs EP; Porter RM; Demarco M; Blanton L; Steffens A; Zhuang Y; Olson N; Barron M; Shifflett P; Schrag SJ; Verani JR; Fry A; Gaglani M; Azziz-Baumgartner E; Klein NP
N Engl J Med; 2021 Oct; 385(15):1355-1371. PubMed ID: 34496194
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
Smith JB; Gonzales EG; Li BH; Langer-Gould A
JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
15. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
16. Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes.
Lin DY; Gu Y; Xu Y; Wheeler B; Young H; Sunny SK; Moore Z; Zeng D
JAMA; 2022 Oct; 328(14):1415-1426. PubMed ID: 36155617
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study.
Chin ET; Leidner D; Zhang Y; Long E; Prince L; Schrag SJ; Verani JR; Wiegand RE; Alarid-Escudero F; Goldhaber-Fiebert JD; Studdert DM; Andrews JR; Salomon JA
Clin Infect Dis; 2022 Aug; 75(1):e838-e845. PubMed ID: 35083482
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
Tartof SY; Slezak JM; Fischer H; Hong V; Ackerson BK; Ranasinghe ON; Frankland TB; Ogun OA; Zamparo JM; Gray S; Valluri SR; Pan K; Angulo FJ; Jodar L; McLaughlin JM
Lancet; 2021 Oct; 398(10309):1407-1416. PubMed ID: 34619098
[TBL] [Abstract][Full Text] [Related]
19. Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study.
Xu S; Sy LS; Hong V; Holmquist KJ; Qian L; Farrington P; Bruxvoort KJ; Klein NP; Fireman B; Han B; Lewin BJ
JMIR Public Health Surveill; 2024 Jun; 10():e53807. PubMed ID: 38916940
[TBL] [Abstract][Full Text] [Related]
20. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
